Tumor Necrosis Factor Alpha Inhibitors May Pose Risk in Ankylosing Spondylitis and Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 21, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

IL-17 Inhibitors in the Treatment of Ankylosing Spondylitis IL-17 Inhibitors in the Treatment of Ankylosing Spondylitis
Several IL-17 inhibitors are approved for the treatment of ankylosing spondylitis, but what do we know about the safety and efficacy of these drugs?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Some Biologics Better Than Others for Averting Anterior Uveitis Some Biologics Better Than Others for Averting Anterior Uveitis
For patients with ankylosing spondylitis or undifferentiated spondyloarthritis, risk for anterior uveitis hinges by disease-modifying antirheumatic drug, a large Swedish cohort study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA
The monoclonal interleukin-17A antagonist has three other indications: ankylosing spondylitis in adults, psoriatic arthritis in adults, and plaque psoriasis in adults and children age 6 and older.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 2, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA INDIANAPOLIS, June 1, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company ... Biopharmaceuticals, FDA Eli Lilly, Taltz, ixekizumab, spondyloarthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 1, 2020 Category: Pharmaceuticals Source Type: news

What Are Early Symptoms of Ankylosing Spondylitis
What Are the Early Symptoms of Ankylosing Spondylitis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - May 22, 2020 Category: General Medicine Source Type: news

‘This Is Really Life or Death.’ For People With Disabilities, Coronavirus Is Making It Harder Than Ever to Receive Care
Jeiri Flores is normally a busy, upbeat 29-year-old. But amid the COVID-19 pandemic, her go-to thought has been dark. “If I get this,” she thinks, “I’m gonna die.” This is not an unfounded fear. Flores has cerebral palsy, uses a wheelchair and needs assistance with everyday tasks, including making food and getting dressed. Her disability means it’s tougher for her immune system to kick illnesses; she’s still recovering from a bout of pneumonia she had in January. So beating COVID-19 could easily mean a protracted battle and months in a hospital—a prospect that comes with a c...
Source: TIME: Health - April 24, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news

The risk of deliberate self-harm following a diagnosis of rheumatoid arthritis or ankylosing spondylitis: a population-based cohort study - Kuriya B, Vigod S, Luo J, Widdifield J, Haroon N.
OBJECTIVE: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with mental illness. The risk of serious mental illness, including deliberate self-harm (DSH), in these conditions is not well known. We aimed to determine if RA or AS inde... (Source: SafetyLit)
Source: SafetyLit - February 26, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Factors That Predict Radiographic Progression of Ankylosing Spondylitis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - February 15, 2020 Category: Orthopaedics Tags: CME Article Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Humid, Windy Days Worse For Pain, Says New Study
(CNN) — Humid, windy days with low pressure make pain worse in those with long-term health conditions, according to new research. People with conditions like arthritis, fibromyalgia, migraine and neuropathic pain are 20% more likely to suffer pain in such weather, reveals a study carried out by scientists from the University of Manchester, UK. “This would mean that, if your chances of a painful day on an average weather day were 5 in 100, they would increase to 6 in 100 on a damp and windy day,” said study author Will Dixon, professor of Digital Epidemiology, in a statement. Relatively high humidity is th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated CBSN Boston CNN Pain Study Source Type: news

Smoking Cessation Effects in Ankylosing Spondylitis Smoking Cessation Effects in Ankylosing Spondylitis
Ankylosing spondylitis patients who quit smoking may realize improvements in disease activity, mobility, and quality of life.Journal of Clinical Rheumatology (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - October 21, 2019 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

CARD9 mediates dendritic cell-induced development of Lyn deficiency-associated autoimmune and inflammatory diseases
CARD9 is an immune adaptor protein in myeloid cells that is involved in C-type lectin signaling and antifungal immunity. CARD9 is implicated in autoimmune and inflammatory-related diseases, such as rheumatoid arthritis, IgA nephropathy, ankylosing spondylitis, and inflammatory bowel disease (IBD). Given that Lyn-deficient (Lyn–/–) mice are susceptible to both autoimmunity and IBD, we investigated the immunological role of CARD9 in the development of these diseases using the Lyn–/– mouse model. We found that genetic deletion of CARD9 was sufficient to reduce the development of both spontaneous autoim...
Source: Signal Transduction Knowledge Environment - October 8, 2019 Category: Science Authors: Ma, J., Abram, C. L., Hu, Y., Lowell, C. A. Tags: STKE Research Articles Source Type: news

Treatment Guidelines Updated for Ankylosing Spondylitis, Axial SpA
WEDNESDAY, Aug. 28, 2019 -- In a special article published online Aug. 21 in Arthritis Care& Research, the American College of Rheumatology, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network present... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Taltz (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 26, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 26, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Aug. 26, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults... Biopharmaceuticals, FDA Eli Lilly, Taltz, ixekizumab, ankylosing spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2019 Category: Pharmaceuticals Source Type: news

Effects of Infliximab Withdrawal and Reintroduction in Ankylosing Spondylitis Patients in Persistent Clinical Remission
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 15, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Withdrawal of Infliximab Therapy in Ankylosing Spondylitis Withdrawal of Infliximab Therapy in Ankylosing Spondylitis
Should infliximab withdrawal be considered for ankylosing spondylitis patients who have achieved clinical remission? What are the effects of reintroduction?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Psoriatic Spondylitis or Ankylosing Spondylitis Psoriasis Psoriatic Spondylitis or Ankylosing Spondylitis Psoriasis
A new review examines the similarities and differences between these conditions, and explores the implications for treatment.Current Opinion in Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Venous Thromboembolism Risk High in Ankylosing Spondylitis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - May 16, 2019 Category: Orthopaedics Tags: Snapshot Source Type: news

FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases
Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - April 30, 2019 Category: Rheumatology Tags: Rheumatology News Alert Source Type: news

Ankylosing Spondylitis and Health-Related Quality of Life
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - April 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

Why do patients turn to the internet for health information?
Lack of trust in physicians, lack of information about biologics, medicine substitutions and the search for alternative therapies are among the reasons patients turn to the internet, a new study shows. (Source: ConsultantLive)
Source: ConsultantLive - March 5, 2019 Category: Internal Medicine Authors: Whitney J. Palmer Tags: Ankylosing Spondylitis Source Type: news

VTE Risk High in Ankylosing Spondylitis (CME/CE)
(MedPage Today) -- Risk of DVT significantly elevated; less risk seen for PE (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 25, 2019 Category: Primary Care Source Type: news

VTE Risk High in Spine Disease
(MedPage Today) -- More deep venous thrombosis than pulmonary embolism seen in ankylosing spondylitis (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - February 14, 2019 Category: Rheumatology Source Type: news

Secukinumab cost-effective option in ankylosing spondylitis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

IBD Risk Low in Patients Taking Secukinumab (CME/CE)
(MedPage Today) -- IBD events rare across 21 clinical trials for patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis given the agent (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 29, 2019 Category: Dermatology Source Type: news

IBD Rates Low in Patients on Cosentyx
(MedPage Today) -- Analysis of data from 21 clinical trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 25, 2019 Category: Dermatology Source Type: news

Patients With Spine Disease Face Lower Health-Related QOL (CME/CE)
(MedPage Today) -- Swedish study finds greater impact on physical versus mental components in ankylosing spondylitis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 7, 2019 Category: Primary Care Source Type: news

Spine Disease Hampers Quality of Life
(MedPage Today) -- But some key factors in ankylosing spondylitis may be modifiable (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 28, 2018 Category: Primary Care Source Type: news

IL-17A Response Independent of CRP in Ankylosing Spondylitis
(MedPage Today) -- Secukinumab effective even with normal levels of inflammatory marker (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 29, 2018 Category: Primary Care Source Type: news

Ixekizumab Improves Outcomes of Ankylosing Spondylitis Ixekizumab Improves Outcomes of Ankylosing Spondylitis
Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 6, 2018 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Long-term Secukinumab Effective for Ankylosing Spondylitis Long-term Secukinumab Effective for Ankylosing Spondylitis
The long-term results are welcome news because about half of patients do not respond to TNF inhibitors, which are the only treatment currently available for ankylosing spondylitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Immune therapy generates promising results in hard-to-treat ankylosing spondylitis
(Wiley) Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis (AS), a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2018 Category: International Medicine & Public Health Source Type: news

Amgen Releases AMGEVITA for Treatment of Inflammatory Diseases in Adults
The AMGEVITA is a biosimilar designed to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis hidradenitis and panuveitis. The biosimilar is a citrate-free formula and will be released in twenty-eight  countries in the European Union.This story is related to the following:Biopharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - October 18, 2018 Category: Medical Devices Source Type: news

Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx ® leadership in spondyloarthritis
Novartis, a leader in immuno-dermatology and rheumatology, announced today it will be presenting five-year data from the ongoing extensions of the phase III FUTURE 1 and MEASURE 1 studies for Cosentyx® (secukinumab) in patients with psoriatic arthritis (PsA)[1] and ankylosing spondylitis (AS)[2] respectively. (Source: World Pharma News)
Source: World Pharma News - October 16, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Amgen Launches AMGEVITA ™ (Biosimilar Adalimumab) In Markets Across Europe
First Inflammation Biosimilar From Amgen's Portfolio to Launch in Europe THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC). AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidenc...
Source: Amgen News Release - October 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Biologics Less Effective for Ankylosing Spondylitis in Women Biologics Less Effective for Ankylosing Spondylitis in Women
Women and men with ankylosing spondylitis respond differently to TNF inhibitor therapy, and researchers are trying to determine why that is.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Stromal Vascular Fraction Treatment for Osteoarthritis Stromal Vascular Fraction Treatment for Osteoarthritis
A novel stem-cell therapy with stromal vascular fraction resulted in dramatic improvements to this patient's osteoarthritis and comorbidities including ankylosing spondylitis, depression, and fatigue.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news

Ankylosing Spondylitis: No Special Infection Risk from Treatment
(MedPage Today) -- DMARDs, TNF inhibitors appear safe in this regard (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 8, 2018 Category: Primary Care Source Type: news

Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
INDIANAPOLIS, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and eff... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Risankizumab Fails in Spine Disease (CME/CE)
(MedPage Today) -- Blocking IL-23 not a winning strategy in ankylosing spondylitis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 27, 2018 Category: Primary Care Source Type: news

Ankylosing Spondylitis Patients at Risk for Self-Harm Ankylosing Spondylitis Patients at Risk for Self-Harm
People with this painful condition that affects the spine are at higher risk of harming themselves, a large study confirms; however, the mental health effects of the disease are often ignored.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Significant increase in self-harm attempts following ankylosing spondylitis diagnosis
(European League Against Rheumatism) The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate a significantly increased rate of self-harm attempts in inflammatory arthritis (IA), particularly following a diagnosis of Ankylosing Spondylitis (AS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2018 Category: International Medicine & Public Health Source Type: news

Combining NSAIDs and TNFi may reduce radiographic progression in ankylosing spondylitis
(European League Against Rheumatism) The results of a cohort study presented at the Annual European Congress of Rheumatology (EULAR 2018) showed that, in patients with ankylosing spondylitis (AS) taking tumour necrosis factor (TNF) inhibitors, the addition of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with significantly less radiographic progression in a dose-related manner at four years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 14, 2018 Category: International Medicine & Public Health Source Type: news

Imagine Dragons' Dan Reynolds opens up on health struggles
Reynolds has ankylosing spondylitis, an inflammatory disease that once caused the singer crippling amounts of pain (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 11, 2018 Category: Consumer Health News Source Type: news

Managing Morbidity and Treatment-Related Toxicity in AS Managing Morbidity and Treatment-Related Toxicity in AS
Find out more about the morbidities associated with ankylosing spondylitis and its treatment, and learn how to best manage them.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Efficacy, Safety, and Tolerability of Secukinumab in AS Efficacy, Safety, and Tolerability of Secukinumab in AS
Is secukinumab a safe and effective treatment choice for patients with ankylosing spondylitis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

EMA Committee Backs Remicade Biosimilar Zessly EMA Committee Backs Remicade Biosimilar Zessly
The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 24, 2018 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news